Browsing Category
Pharma Industry News
4141 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How CLD-401 and RedTail may redefine tumor-localized immune activation in solid tumors
Can RedTail and CLD-401 change solid tumor immunotherapy? Read why Calidi Biotherapeutics, Inc.’s next milestones could reshape the CLDI story.
Why oncology investors are watching Cogent Biosciences, Inc.’s PEAK data closely
Why investors are closely watching Cogent Biosciences’ PEAK data and what bezuclastinib could mean for valuation, revenue growth, and oncology market sentiment.
Lilly bets $7.8bn on orexin science with Centessa acquisition as neuroscience race intensifies
Eli Lilly agrees to acquire Centessa Pharmaceuticals for $6.3B, gaining orexin sleep drug cleminorexton. Read the full strategic analysis.
What the CHMP’s positive view on lomitapide reveals about the evolving HoFH treatment landscape in children
See how Chiesi Group’s paediatric lomitapide expansion could reshape HoFH treatment access, payer dynamics, and rare disease growth across Europe.
FDA approves Lilly’s Foundayo as second oral GLP-1 weight loss pill, challenging Novo Nordisk’s head start
FDA approves Eli Lilly's Foundayo (orforglipron), the second oral GLP-1 obesity pill with no food restrictions. What this means for LLY investors and patients. Read more.
What clinicians may watch next in Evaxion A/S’s artificial intelligence vaccine platform
What clinicians and investors may watch next in Evaxion A/S’s AI vaccine platform as polio and CMV programs test the commercial case for TechBio innovation.
Avacta (AIM: AVCT) investor roadmap: The milestones that matter between now and the AVA6103 data readout in late 2026
Avacta (AVCT) faces two clinical data readouts in 2026. This investor roadmap maps every milestone, risk, and signal to watch through the AVA6103 Phase 1 readout.
GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn
GSK retains 78.3% of ViiV Healthcare as Shionogi doubles its stake to 21.7% for $2.125 bn and Pfizer exits. Read the full strategic analysis.
Saharsh Davuluri takes helm at Neuland Laboratories as CDMO accelerates push into commercial NCE contracts
Saharsh Davuluri takes over as CEO of Neuland Laboratories, steering the Indian CDMO into an aggressive peptide and NCE expansion. Read what this means for investors and competitors.
Neurizon Therapeutics (ASX: NUZ) NUZ-001 activates dual protein clearance pathways in ALS neuronal study
Neurizon Therapeutics NUZ-001 activates two protein clearance pathways in ALS neurons. Read what the preclinical data means ahead of the HEALEY trial.